Compare Johnson & Johnson (JNJ) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Main Street Capital Corporation — how do they compare? Johnson & Johnson trades at $260.35 (market cap $626.09B), while Main Street Capital Corporation trades at $58.41 (market cap $5.52B). The key difference: Johnson & Johnson is far larger — about 113.4× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.39%). Which is the better fit depends on your goals.
| JNJ | MAIN | |
|---|---|---|
Market Cap | $626.09B | $5.52B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $67.54 |
52-Week Low | $172.78 | $49.63 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 5.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Main Street Capital (MAIN) trades at $59.10, up 0.99% with a bullish technical outlook. The stock shows strong fundamentals with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings missed estimates. Recent news highlights MAIN's dividend reliability amid sector challenges, with the company maintaining payouts while peers face cuts. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $59-60.
MAIN offers stable income with consistent dividends but faces headwinds from declining revenue projections ($592M in 2025 to $559M in 2026). Analyst consensus is cautious with 78.57% hold ratings and a $56.67 price target below current levels. Key risks include BDC sector pressure and expense growth impacting earnings coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
